Published on
May 1, 2025
Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma
Introduction Acral melanoma (AM) is a highly aggressive tumor with a 5-year survival rate of approximately 50%.1 In the Asian population, AM is the most common melanoma subtype, with an incidence of around 40%.2 Genetically, AM differs significantly from …
Source:
Dove Medical Press
-
Neutral
